HELP · Nasdaq · CIK 0001833141

Helus Pharma Inc.

Helus Pharma Inc.’s most recent SEC filing in our snapshot is a Form 6-K filed on Oct 27, 2026. Its EDGAR record lists 11 Form 4 insider filings from the 12 months before our last refresh.

SEC EDGAR snapshot updated Oct 27, 2026, 11:27 PM EDT. See all filings on sec.gov.

Revenue, FY2025
—
Net income, FY2025
-CAD 113.1M
Form 4 filings on record, past 12 months
11

Company overview

Legal name (as filed)
Helus Pharma Inc.
Ticker
HELP
SEC Central Index Key (CIK)
0001833141
Industry (SIC)
Pharmaceutical Preparations (code 2834)
Business address
TORONTO
State or country of incorporation
British Columbia, Canada
Fiscal year ends
March 31
SEC filer category
<br>Emerging growth company
Position in SEC ticker list
#2599 of the 3,000 companies we track

Five-year financial highlights

Full-year figures from Helus Pharma Inc.’s annual reports, as tagged in XBRL and published by the SEC. Amounts are in CAD; the fiscal year is named for the calendar year in which it ends.

Revenue
CAD 864.0KFY2021CAD 0FY2022n/aFY2023n/aFY2024n/aFY2025
Net income
-CAD 32.2MFY2021-CAD 67.6MFY2022-CAD 47.5MFY2023-CAD 78.1MFY2024-CAD 113.1MFY2025
HELP annual results
ItemFY2021
ended Mar 31, 2021		FY2022
ended Mar 31, 2022		FY2023
ended Mar 31, 2023		FY2024
ended Mar 31, 2024		FY2025
ended Mar 31, 2025
RevenueCAD 864.0KCAD 0———
Net income-CAD 32.2M-CAD 67.6M-CAD 47.5M-CAD 78.1M-CAD 113.1M
Diluted EPS-CAD 0.32-CAD 0.40-CAD 0.26——
Total assetsCAD 92.1MCAD 84.1MCAD 53.9MCAD 302.0MCAD 258.6M
Cash and equivalentsCAD 64.0MCAD 53.6MCAD 16.6MCAD 209.0MCAD 135.0M

XBRL tags used: revenue = Revenue; netIncome = ProfitLoss; assets = Assets; eps = DilutedEarningsLossPerShare; cash = Cash. EPS is shown as originally reported for each year and may not be adjusted for later stock splits. A dash means the company did not report that item in a form we could match.

How to read these numbers

Revenue is the money a company brings in from selling its products and services; net income is what is left after all expenses, interest and taxes. Diluted EPS spreads net income across every share that could exist if options and convertible securities were exercised. Total assets and cash are balance-sheet figures measured on the last day of the fiscal year. For the full story — segment results, one-time charges, guidance — read Management’s Discussion and Analysis in the Form 10-K.

Latest key reports

The most recent filing of each major report type, even if it falls outside the 40 newest filings below.

HELP latest annual, quarterly, current and proxy reports
FiledFormWhat it isOriginal
Oct 27, 20266-KReport of a foreign private issuer· period Oct 27, 2026Document · Index
Jun 29, 202640-FAnnual report of certain Canadian issuers· period Mar 31, 2026Document · Index

Recent SEC filings

The 40 newest documents filed by or about Helus Pharma Inc., by form type:

6-K ×144 ×113 ×10SCHEDULE 13D ×2D ×2S-8 ×1
HELP recent filings
FiledFormWhat it isOriginal
Oct 27, 20266-KReport of a foreign private issuer· period Oct 27, 2026Document · Index
Oct 26, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 26, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 23, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 23, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 23, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 23, 20263Initial statement of beneficial ownership· period Oct 13, 2026Document · Index
Oct 21, 20266-KReport of a foreign private issuer· period Oct 21, 2026Document · Index
Oct 15, 20266-KReport of a foreign private issuer· period Oct 15, 2026Document · Index
Oct 8, 20266-KReport of a foreign private issuer· period Oct 8, 2026Document · Index
Oct 5, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Oct 2, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Oct 1, 20266-KReport of a foreign private issuer· period Oct 1, 2026Document · Index
Oct 1, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Oct 1, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 29, 2026Document · Index
Oct 1, 20263Initial statement of beneficial ownership· period Sep 29, 2026Document · Index
Oct 1, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 30, 2026Document · Index
Sep 23, 20266-KReport of a foreign private issuer· period Sep 22, 2026Document · Index
Sep 22, 20266-KReport of a foreign private issuer· period Sep 21, 2026Document · Index
Sep 21, 20266-KReport of a foreign private issuer· period Sep 21, 2026Document · Index
Sep 21, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 21, 2026Document · Index
Sep 17, 20263Initial statement of beneficial ownership· period Sep 17, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 11, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 8, 2026Document · Index
Sep 10, 20266-KReport of a foreign private issuer· period Sep 10, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 4, 2026Document · Index
Sep 10, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 3, 2026Document · Index
Sep 9, 20266-KReport of a foreign private issuer· period Sep 9, 2026Document · Index
Sep 9, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Sep 1, 2026Document · Index
Sep 9, 20263Initial statement of beneficial ownership· period Sep 1, 2026Document · Index
Sep 9, 2026SCHEDULE 13DActive beneficial ownership report (over 5%)Document · Index
Sep 9, 20264Statement of changes in beneficial ownership (insider trade)· period Aug 31, 2026Document · Index
Sep 9, 20263Initial statement of beneficial ownership· period Aug 31, 2026Document · Index
Sep 3, 20266-KReport of a foreign private issuer· period Sep 3, 2026Document · Index
Sep 1, 2026S-8Registration of employee benefit plan securitiesDocument · Index
Sep 1, 2026DDDocument · Index
Aug 19, 20266-KReport of a foreign private issuer· period Aug 18, 2026Document · Index
Aug 19, 2026DDDocument · Index

Insider filing activity

11 Form 4 filings appear in Helus Pharma Inc.’s EDGAR record between Oct 28, 2025 and our last refresh. Most are reports by the company’s own directors, officers and 10% owners, but EDGAR also lists a Form 4 under a company when the company itself is the insider — for example, when it owns more than 10% of another public company. Foreign private issuers’ own insiders generally do not file Form 4. A high count is not by itself a signal: many Form 4s report routine stock awards, tax withholding or sales under pre-arranged Rule 10b5-1 plans. Open each filing to see the transaction code, share count and price. What a Form 4 shows.

Other companies in Pharmaceutical Preparations

All 194 companies in Pharmaceutical Preparations

On Amazon

Popular tools for investors

As an Amazon Associate I earn from qualifying purchases.

Electronics Plaud Note Pro AI Voice Recorder An AI voice recorder that turns earnings calls and meetings into notes. View on Amazon → Electronics Amazon Kindle Paperwhite Signature Edition 32GB Read investing classics and long reports without eye strain. View on Amazon → Electronics Apple 2026 MacBook Air 13-inch Laptop A lightweight laptop for spreadsheets and filing research. View on Amazon →

Source

  • U.S. Securities and Exchange Commission, EDGAR submissions for CIK 0001833141 and XBRL company facts. Helus Pharma Inc. on EDGAR.
  • Snapshot updated Oct 27, 2026, 11:27 PM EDT. The SEC does not endorse OpenFilings. Company names and tickers are used only to identify the filer; no logos are shown.

Not investment advice. This page summarizes public SEC filings for information only. Figures may contain errors or omissions; confirm everything in the original filing before relying on it.